242 related articles for article (PubMed ID: 17147833)
21. The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa.
Vickerman P; Devine A; Foss AM; Delany-Moretlwe S; Mayaud P; Meyer-Rath G
Sex Transm Dis; 2011 May; 38(5):401-9. PubMed ID: 21317689
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial.
Locker GY; Mansel R; Cella D; Dobrez D; Sorensen S; Gandhi SK;
Breast Cancer Res Treat; 2007 Dec; 106(2):229-38. PubMed ID: 17245540
[TBL] [Abstract][Full Text] [Related]
23. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
24. Surgery for degenerative cervical myelopathy: a patient-centered quality of life and health economic evaluation.
Witiw CD; Tetreault LA; Smieliauskas F; Kopjar B; Massicotte EM; Fehlings MG
Spine J; 2017 Jan; 17(1):15-25. PubMed ID: 27793760
[TBL] [Abstract][Full Text] [Related]
25. Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Sep; 10(5):331-42. PubMed ID: 22853743
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness and feasibility of conditional economic incentives and motivational interviewing to improve HIV health outcomes of adolescents living with HIV in Anambra State, Nigeria.
Ekwunife OI; Ofomata CJ; Okafor CE; Anetoh MU; Kalu SO; Ele PU; Eleje GU
BMC Health Serv Res; 2021 Jul; 21(1):685. PubMed ID: 34247604
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
Li X; Stander MP; Van Kriekinge G; Demarteau N
BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918
[TBL] [Abstract][Full Text] [Related]
28. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective.
Marcellusi A; Viti R; Russo S; Andreoni M; Antinori A; Mennini FS
Clin Drug Investig; 2016 May; 36(5):377-87. PubMed ID: 26940802
[TBL] [Abstract][Full Text] [Related]
29. Comparative outcomes and cost-utility following surgical treatment of focal lumbar spinal stenosis compared with osteoarthritis of the hip or knee: part 2--estimated lifetime incremental cost-utility ratios.
Rampersaud YR; Tso P; Walker KR; Lewis SJ; Davey JR; Mahomed NN; Coyte PC
Spine J; 2014 Feb; 14(2):244-54. PubMed ID: 24239803
[TBL] [Abstract][Full Text] [Related]
30. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
31. Multi-country analysis of treatment costs for HIV/AIDS (MATCH): facility-level ART unit cost analysis in Ethiopia, Malawi, Rwanda, South Africa and Zambia.
Tagar E; Sundaram M; Condliffe K; Matatiyo B; Chimbwandira F; Chilima B; Mwanamanga R; Moyo C; Chitah BM; Nyemazi JP; Assefa Y; Pillay Y; Mayer S; Shear L; Dain M; Hurley R; Kumar R; McCarthy T; Batra P; Gwinnell D; Diamond S; Over M
PLoS One; 2014; 9(11):e108304. PubMed ID: 25389777
[TBL] [Abstract][Full Text] [Related]
32. Adherence clubs for long-term provision of antiretroviral therapy: cost-effectiveness and access analysis from Khayelitsha, South Africa.
Bango F; Ashmore J; Wilkinson L; van Cutsem G; Cleary S
Trop Med Int Health; 2016 Sep; 21(9):1115-23. PubMed ID: 27300077
[TBL] [Abstract][Full Text] [Related]
33. Transmission reduction, health benefits, and upper-bound costs of interventions to improve retention on antiretroviral therapy: a combined analysis of three mathematical models.
Bershteyn A; Jamieson L; Kim HY; Platais I; Milali MP; Mudimu E; Ten Brink D; Martin-Hughes R; Kelly SL; Phillips AN; Bansi-Matharu L; Cambiano V; Revill P; Meyer-Rath G; Nichols BE
Lancet Glob Health; 2022 Sep; 10(9):e1298-e1306. PubMed ID: 35961353
[TBL] [Abstract][Full Text] [Related]
34. Modelling the cost effectiveness of antidepressant treatment in primary care.
Revicki DA; Brown RE; Palmer W; Bakish D; Rosser WW; Anton SF; Feeny D
Pharmacoeconomics; 1995 Dec; 8(6):524-40. PubMed ID: 10160081
[TBL] [Abstract][Full Text] [Related]
35. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings.
Bishai D; Colchero A; Durack DT
AIDS; 2007 Jun; 21(10):1333-40. PubMed ID: 17545710
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of embryo transfer strategies: a decision analytic model using long-term costs and consequences of singletons and multiples born as a consequence of IVF.
van Heesch MM; van Asselt AD; Evers JL; van der Hoeven MA; Dumoulin JC; van Beijsterveldt CE; Bonsel GJ; Dykgraaf RH; van Goudoever JB; Koopman-Esseboom C; Nelen WL; Steiner K; Tamminga P; Tonch N; Torrance HL; Dirksen CD
Hum Reprod; 2016 Nov; 31(11):2527-2540. PubMed ID: 27907897
[TBL] [Abstract][Full Text] [Related]
37. Financing equitable access to antiretroviral treatment in South Africa.
Cleary S; McIntyre D
BMC Health Serv Res; 2010 Jul; 10 Suppl 1(Suppl 1):S2. PubMed ID: 20594368
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
